New data confirms superiority of docetaxel based triplet therapy in gastric cancer #ESMO17

da Salute H24 — 8 settembre 2017 alle 16:55


The superiority of docetaxel based triplet therapy over standard care in patients with resectable oesophago-gastric cancer has been confirmed in late-breaking results from the FLOT4 trial presented at the ESMO 2017 Congress in Madrid. 

Survival in resectable oesophago-gastric cancer is poor. Continua »

AntonioCaperna

Scrivi un commento